Search Results - Linmei Zhou

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese... by Tao Wang, Zhiwei Cui, Yingyong Ou, Siyu Lou, Huayou Chen, Chengyu Zhu, Linmei Zhou, Fan Zou

    Published in Frontiers in Pharmacology (2025-04-01)
    Get full text
    Article


  2. 2

    Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024 by Siyu Lou, Huayou Chen, Zhiwei Cui, Xiyuan Zhang, Chengyu Zhu, Linmei Zhou, Yingyong Ou, Fan Zou

    Published in Frontiers in Pharmacology (2025-06-01)
    Get full text
    Article


  3. 3

    Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups by Yingyong Ou, Zhiwei Cui, Siyu Lou, Chengyu Zhu, Junyou Chen, Linmei Zhou, Ruizhen Zhao, Li Wang, Fan Zou

    Published in Frontiers in Pharmacology (2024-11-01)
    Get full text
    Article


  4. 4

    A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases by Siyu Lou, Zhiwei Cui, Yingyong Ou, Junyou Chen, Linmei Zhou, Ruizhen Zhao, Chengyu Zhu, Li Wang, Zhu Wu, Fan Zou

    Published in BMC Psychiatry (2025-01-01)
    Get full text
    Article


  5. 5

    Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system by Chengyu Zhu, Zhiwei Cui, Tingting Liu, Siyu Lou, Linmei Zhou, Junyou Chen, Ruizhen Zhao, Li Wang, Yingyong Ou, Fan Zou

    Published in Frontiers in Pharmacology (2025-03-01)
    Get full text
    Article


Search Tools: